Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy (Q33331776)

25 July 2017

title

Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy (English)

1 reference

25 July 2017

1 reference

1 reference

Gregory RK

1

1 reference

25 July 2017

Hill ME

2

1 reference

25 July 2017

Moore J

3

1 reference

25 July 2017

A'Hern RP

4

1 reference

25 July 2017

Johnston SR

5

1 reference

25 July 2017

Blake P

6

1 reference

25 July 2017

Shephard J

7

1 reference

25 July 2017

Barton D

8

1 reference

25 July 2017

Gore ME

9

1 reference

25 July 2017

publication date

1 March 2000

1 reference

European Journal of Cancer

25 July 2017

published in

1 reference

25 July 2017

volume

36

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

503-507

1 reference

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Impact of doxorubicin on survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900309-3

7 January 2021

10.1016/S0959-8049(99)00309-3

Identifiers

DOI

1 reference

25 July 2017

1 reference